A randomized, double-blind, placebo-controlled, single-ascending-dose study in healthy volunteers and a double-blind, placebo-controlled, multiple-ascending-dose study in patients with Parkinson’s disease to evaluate the safety, tolerability, and PK/PD of LY3962681.

2024-513411-27-00 Protocol J5F-MC-OOAA Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 4 sites · Protocol J5F-MC-OOAA

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 124
Countries 2
Sites 4

Parkinson’s disease

Key facts

Sponsor
Prevail Therapeutics Inc.
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Decision date (initial)
2025-04-01
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-513411-27-00
ClinicalTrials.gov
NCT06565195

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Parkinson’s disease

VersionLevelCodeTermSystem organ class
20.0 PT 10061536 Parkinson's disease 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Prevail Therapeutics Inc.

Sponsor organisation
Prevail Therapeutics Inc.
Address
645 Summer Street
City
Boston
Postcode
02210-2135
Country
United States

Scientific contact point

Organisation
Prevail Therapeutics Inc.
Contact name
Regulatory Department

Public contact point

Organisation
Prevail Therapeutics Inc.
Contact name
Regulatory Department

Locations

2 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Authorised, recruitment pending 7 2
Netherlands Authorised, recruitment pending 3 2
Rest of world
United Kingdom, United States, Japan
114

Investigational sites

Germany

2 sites · Authorised, recruitment pending
Universitaetsklinikum Duesseldorf AöR
Zentrum für Bewegungsstörungen und Neuromodulation, Moorenstrasse 5, Bilk, Duesseldorf
Universitaet Muenster
Klinik für Neurologie mit Institut für Translationale Neurologie, Albert-Schweitzer-Campus 1, Sentrup, Muenster

Netherlands

2 sites · Authorised, recruitment pending
Radboud universitair medisch centrum Stichting
Neurological Movement Disorders, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen
CTC Netherlands BV
Neurology, Hanzeplein 1,entrance 53, 9713 GZ, Groningen

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-27 Germany Acceptable
2025-03-31
2025-04-01
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-11-13 Germany Acceptable
2025-03-31
2025-11-13
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-04 Germany Acceptable
2026-03-16
2026-03-17
4 SUBSTANTIAL MODIFICATION SM-3 2026-04-16 Germany Acceptable
2026-06-01
2026-06-02